[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hodgkins-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hodgkins-disease":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,75,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100067525","establishing-a-tumor-bank-in-families-with-multiple-lymphoproliferative-malignancies-100067525",false,"NCT00131014","Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies","Establishing a Tumor Bank and Initial Analysis of Germline and Tumor-Related Genetic Alterations in Families With Multiple Lymphoproliferative Malignancies","Inclusion Criteria:\n\n* Any individual diagnosed with non-Hodgkin's lymphoma or Hodgkin's disease or chronic lymphocytic leukemia (CLL), who has a 1st degree relative (parent, sibling or child) with a lymphoproliferative disorder; or families in which the individual has a lymphoproliferative disorder, and an unusual clustering of frequent or premature solid tumors is also observed.\n* Family members of the individual, either affected or unaffected with lymphoma, who are contacted by the individual and agree to participate in the study.\n* Deceased family members may be included in the study. Public records such as death certificates may be used to confirm the history. Consent for medical records or tissue blocks will be obtained from the deceased family member's next of kin. The hierarchy of relatives defined as next of kin is spouse, offspring, parents and siblings. Archived tissue samples may be used for genetic research.\n* Age \\> 18 years\n\nExclusion Criteria:\n\n* Subjects without a family history of lymphoma","ALL","18 Years",{"count":19,"type":20},1500,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma.",[24,25,26,27],"Non-Hodgkin's Lymphoma","Hodgkin's Disease","Leukemia, Lymphocytic, Chronic","Lymphoproliferative Disorders",[24,29,30,31,32],"Hodgkin's disease","Chronic Lymphocytic Leukemia","Lymphoproliferative disorder","Genetics","RECRUITING","2026-04-21",{"date":36,"type":37},"2026-04-24","ACTUAL",{"date":39,"type":37},"2004-08-09",{"date":41,"type":20},"2033-01",{"name":43,"class":44},"Dana-Farber Cancer Institute","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":56,"studyType":21,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100200817","the-prospective-collection-storage-and-reporting-of-data-on-patients-undergoing-hematopoietic-stem-cell-transplantation-utilizing-a-standard-preparative-regimen-100200817","NCT01890486","The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen","The Prospective Collection, Storage and Reporting of Data on Patients","Inclusion Criteria:\n\nPlanned standard of care dose intensive therapy and either an allogeneic or autologous bone marrow transplant\n\nExclusion Criteria:\n\nParticipation in any other treatment research protocol","120 Years",{"count":55,"type":20},2000,"1 Year","To provide the IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed.",[59,60,61,24,25,62,63,64,30,65],"Acute Myelogenous Leukemia","Acute Lymphocytic Leukemia","Chronic Myelogenous Leukemia","Multiple Myeloma","Germ Cell Neoplasms","Myelodysplastic Syndromes","Immunodeficiency Diseases","2026-04-09",{"date":68,"type":37},"2026-04-13",{"date":70,"type":37},"2001-05-21",{"date":72,"type":20},"2026-12",{"name":74,"class":44},"Wake Forest University Health Sciences",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100175292","phase-1-cytotoxic-t-lymphocytes-for-ebv-positive-lymphoma-grale-100175292","NCT01555892","Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE","Administration of Rapidly Generated EBV-Specific Cytotoxic T-Lymphocytes To Patients With EBV-Positive Lymphoma","GRALE","Inclusion Criteria at time of Procurement\n\n1. Any patient, regardless of age or sex, with EBV-positive Hodgkin's or non-Hodgkin's Lymphoma, (regardless of the histological subtype) or EBV (associated)-T\u002FNK-lymphoproliferative disease or Severe Chronic Active EBV (CAEBV) who may subsequently be eligible for the treatment component\n2. EBV positive tumor (can be pending at this time)\n3. Weighs at least 12kg\n4. Informed consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent.\n\nInclusion Criteria at time of Infusion\n\n1. Any patient, regardless of age or sex, with EBV-positive Hodgkin's or non-Hodgkin's Lymphoma (regardless of histologic subtype), or EBV (associated)-T\u002FNK-lymphoproliferative disease or Severe Chronic Active EBV (CAEBV)\\* and\n\n   In second or subsequent relapse (or first relapse or with active disease if immunosuppressive chemotherapy contraindicated or multiply relapsed patients in remission who have a high risk of relapse)\\*\\* OR any patient with primary disease or in first remission if immunosuppressive chemotherapy is contraindicated, e.g. patients who develop Hodgkin disease after solid organ transplantation or if the Lymphoma is a second malignancy e.g. a Richter's transformation of CLL. (Group A)\n\n   OR\n\n   In remission or with minimal residual disease status after autologous or syngeneic SCT. (Group B)\n2. EBV positive tumor\n3. Patients with bilirubin less than or equal to 3x upper limit of normal, AST less than or equal 5x upper limit of normal, and hemoglobin greater than or equal to 7.0 (may be a transfused value).\n4. Patients with a creatinine less than or equal to 2x upper limit of normal for age\n5. Pulse oximetry of \\> 90% on room air\n6. Patients should have been off other investigational therapy for 4 weeks prior to entry in this study. PD1\u002FPDL inhibitors will be allowed if medically indicated.\n7. Patients with a Karnofsky\u002FLansky score of greater than or equal to 50\n8. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded.\n9. Informed consent explained to, understood and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent.\n\n   * CAEBV is defined as patients with high EBV viral load in plasma or PBMC (\\> 4000 genomes per ug PBMC DNA) and\u002For biopsy tissue positive for EBV\n\n     * Patients with relapsed or refractory lymphoma that are eligible for a stem cell transplant will not be treated on this study as an alternative to transplant.\n\nExclusion Criteria at Time of Procurement\n\n1\\. Active infection with HIV, HTLV, HBV, HCV (can be pending at this time)\n\nExclusion Criteria at Time of Infusion\n\n1. Pregnant or lactating\n2. Severe intercurrent infection.\n3. Current use of systemic corticosteroids \\> 0.5 mg\u002Fkg\u002Fday",{"count":84,"type":20},136,"INTERVENTIONAL",[87],"PHASE1","Subjects have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T\u002FNK-lymphoproliferative disease or severe chronic active Epstein Barr Virus (CAEBV) which has come back, is at risk of coming back, or has not gone away after treatment, including the best treatment investigators know for these diseases.\n\nSome of these patients show signs of virus that is called Epstein Barr virus (EBV) that causes mononucleosis or glandular fever (\"mono\" or the \"kissing disease\") before or at the time of their diagnosis. EBV is found in the cancer cells of up to half the patients with HD and NHL, suggesting that it may play a role in causing Lymphoma. The cancer cells and some immune system cells infected by EBV are able to hide from the body's immune system and escape destruction. Investigators want to see if special white blood cells, called GRALE T cells, that have been trained to kill EBV infected cells can survive in the blood and affect the tumor.\n\nInvestigators have used this sort of therapy to treat a different type of cancer called post transplant lymphoma. In this type of cancer the tumor cells have 9 proteins made by EBV on their surface. Investigators grew T cells in the lab that recognized all 9 proteins and were able to successfully prevent and treat post transplant lymphoma. However, in HD and NHL, T\u002FNK-lymphoproliferative disease, and CAEBV, the tumor cells and B cells only express 4 EBV proteins. In a previous study, the investigators made T cells that recognized all 9 proteins and gave them to patients with HD. Some patients had a partial response to this therapy but no patients had a complete response. The investigators then did follow up studies where investigators made T cells that recognized the 2 EBV proteins seen in patients with lymphoma, T\u002FNK-lymphoproliferative disease and CAEBV. Investigators have treated over 50 people on those studies. About 60% of those patients who had disease at the time they got the cells had responses including some patients with complete responses. This study will expand on those results and the investigators will try and make the T cells in the lab in a simpler faster way. These cells are called GRALE T cells. These GRALE T cells are an investigational product not approved by the FDA.\n\nThe purpose of this study is to find the largest safe dose of LMP-specific cytotoxic GRALE T cells created using this new manufacturing technique. Investigators will learn what the side effects are and to see whether this therapy might help patients with HD or NHL or EBV associated T\u002FNK-lymphoproliferative disease or CAEBV.",[25,24,90,91],"Lymphoproliferative Disease","Lymphoma",[93,94,24,95,96,97,98,99,100],"EBV","Hodgkin's Lymphoma","Lymphoma Relapse","Autologous or Syngeneic Stem Cell Transplant","T\u002FNK-lymphoproliferative disease","LMP","BARF1","EBNA1","2026-02-26",{"date":103,"type":37},"2026-03-02",{"date":105,"type":37},"2013-01-14",{"date":107,"type":20},"2027-07-01",{"name":109,"class":44},"Baylor College of Medicine",3,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":45},"100087542","clinical-and-pathologic-studies-in-non-hodgkins-lymphoma-and-hodgkins-disease-100087542","NCT00398177","Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease","Inclusion Criteria:\n\n* Diagnosis of Hodgkin's disease or non-Hodgkin's lymphoma, any cellular classification, any stage, any grade.\n* Adult or pediatric patients receiving lymph node excision for purposes other than cancer therapy (i.e. tonsillectomy, sleep apnea).\n* A routine procedure for tissue collection is planned.\n* Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Patients without NHL or Hodgkin's disease",{"count":118,"type":20},9999,"The purpose of this study is to characterize the molecular and cell biology of the tumor cells in lymphoma.",[121,25],"Lymphoma, Non-Hodgkin","2025-12-17",{"date":124,"type":37},"2025-12-24",{"date":126,"type":4},"1999-01",{"date":128,"type":20},"2099-01",{"name":130,"class":44},"Stanford University"]